Ligand Q1 revenue rises 14% on royalty growth

Ligand Pharmaceuticals Incorporated

07/05/2026 12:20

Overview

Royalty aggregator's Q1 revenue rose 14% yr/yr, driven by 56% royalty revenue growth

Adjusted EPS for Q1 grew 23% yr/yr, mainly on higher royalty revenue

Company reaffirmed 2026 full-year guidance, reflecting anticipated partial-year XOMA contribution

Outlook

Ligand reaffirms 2026 adjusted EPS guidance of $8.50 to $9.50

Company sees 2026 royalty revenue of $225 mln to $250 mln

Ligand expects 2026 total revenue of $270 mln to $310 mln

Result Drivers

ROYALTY REVENUE SURGE - 56% yr/yr royalty revenue growth, mainly from Filspari, Ohtuvayre and Capvaxive, drove results

FILSPARI FDA APPROVAL - Full FDA approval of Filspari in FSGS strengthened royalty portfolio and boosted royalty income

CAPTISOL SALES DECLINE - Captisol sales fell due to timing of customer orders, partially offsetting revenue growth

Company press release: ID:nGNX13hhSc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.67
Q1 Net Income
-$13.35 mln
Q1 Basic EPS
-$0.67
Q1 Operating Income
$17.37 mln
Q1 Pretax Profit
-$24.26 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)